Top Markets
#1 Purr Purr +58.83%
#2 Smilek to the Bank Smilek to the Bank +50.56%
#3 Pons Pons +25.62%
#4 ApeX ApeX +21.70%
#5 Fake World Assets Fake World Assets +20.54%
#6 Not in Employment, Education, or Training Not in Employment, Education, or Training +19.66%
#7 Non-Playable Coin Non-Playable Coin +18.45%
#8 Kinetiq Kinetiq +17.78%
#9 Zora Zora +17.54%
#10 OriginTrail OriginTrail +17.24%
Coin of the day
Purr Purr
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

4568
Classificação em ações #758
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively... Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer's disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.
Preço da ação
$18.49
Última sincronização: 2026-08-21
Valor de mercado
$33.64B
Variação (1 dia)
-1.19%
Variação (1 ano)
-25.90%
País
JP
Negociar Daiichi Sankyo Company, Limited (4568)

Categoria

Healthcare
Rácio P/E de Daiichi Sankyo Company, Limited (4568)
Rácio P/E em 2026 TTM: 0
De acordo com os últimos relatórios financeiros e o preço das ações da Daiichi Sankyo Company, Limited, o rácio P/E atual (TTM) é 0. No final de 2026, a empresa tinha um P/E de 0.
Histórico do rácio P/E da Daiichi Sankyo Company, Limited de 2026 a 2026
Rácio P/E no final de cada ano
Ano Índice P/E Alterar
Não há dados suficientes para as datas fornecidas.
Rácio P/E para empresas semelhantes ou concorrentes
Empresa Rácio P/E Diferença do rácio P/E País
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 39.54 -
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 30.10 -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 70.28 -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 22.25 -
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 107.81 -
US
Como interpretar um P/E Ratio?

O rácio Preço/Lucro (P/E) mede a relação entre o preço da ação de uma empresa e o lucro por ação.
Um P/E baixo mas positivo representa uma empresa com altos lucros face à sua valorização atual e pode estar subvalorizada. Um P/E negativo elevado (perto de 0) representa perdas significativas.

Empresas com P/E acima de 30 ou negativo são geralmente vistas como "ações de crescimento", significando que os investidores esperam crescimento ou rentabilidade futura.

Empresas com P/E positivo inferior a 10 são geralmente consideradas "ações de valor", ou seja, já são muito lucrativas mas com pouco potencial de crescimento.